FDA-Approved Ketamine Spray Gives Hope to Depression Patients

Ellen Talmage used to need anxiety medication just to visit the grocery store, often breaking down in tears during shopping trips. Today, the 66-year-old grandmother is taking her grandkids to the beach, thanks to a revolutionary depression treatment that changed everything.

Mather Hospital on Long Island is using Spravato, an FDA-approved esketamine nasal spray, to treat patients with severe clinical depression. For Talmage, who struggled for decades on traditional antidepressants like Prozac, the results have been life changing.

"I booked tickets once to a really expensive concert for my birthday, and I couldn't go," Talmage recalled about her life before treatment. "You miss out on a lot of Christmases."

The treatment works differently than conventional antidepressants. Instead of targeting hormones like serotonin, the spray focuses on NMDA receptors at the cellular level. This completely different pathway is showing remarkable results for people who haven't responded to other medications.

Out of nearly 40 patients in Mather's program, 62% report significant improvements in their symptoms. The multiweek program starts with low doses administered twice weekly under medical supervision, gradually increasing as patients respond.

Safety remains the top priority. Patients stay for two hours after each session in comfortable monitoring areas with TV and music. Dr. Erin Dainer, Mather Hospital's psychiatry chair, emphasized the strict regulations surrounding the treatment, especially given concerns about recreational ketamine misuse.

"From going to not being able to get out of bed and dress yourself to thinking about the future and having a job and having a purpose and meaning in life," Dainer said. "I don't see that with other treatments the way I do with this."

The Ripple Effect

The impact extends beyond individual recovery. One anonymous patient found the treatment gave him courage to pursue becoming a peer counselor, helping others who suffer from depression. The combination of ketamine therapy and helping others gave him something he'd lost: a sense of purpose.

Dr. Paniz Johari, a psychiatrist at Mather, believes FDA-approved esketamine will fundamentally shift how doctors manage treatment-resistant depression within the next decade. For patients like Talmage, that future is already here.

The grandmother who once couldn't face a concert now looks forward to beach days with her family, living the life depression once stole from her.